Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    REACH-B Score for Hepatocellular Carcinoma (HCC)

    Estimates risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B.
    Pearls/Pitfalls

    • Derived and validated primarily in East Asian cohorts; may have limited applicability to other populations.

    • Excludes factors such as alpha fetoprotein and alcohol use, which are also known to be associated with progression to cirrhosis and HCC.

    Female
    0
    Male
    +2
    30–34
    0
    35–39
    +1
    40–44
    +2
    45–49
    +3
    50–54
    +4
    55–59
    +5
    60–65
    +6
    <15
    0
    15–44
    +1
    ≥45
    +2
    Negative
    0
    Positive
    +2
    <300 (undetectable)
    0
    300–9,999
    0
    10,000–99,999
    +3
    100,000–999,999
    +5
    ≥10⁶
    +4

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights
    Dr. Hwai-I Yang

    About the Creator

    Hwai-I Yang, PhD, is an associate research fellow at the Genomics Research Center in Taipei, Taiwan. He is also an adjunct associate professor at the Graduate Institute of Clinical Medicine at National Yang-Ming University. Dr. Yang’s primary research is focused on hepatitis epidemiology, translational epidemiology, immunoepidemiology of viral hepatitis, and immunoprevention of major cancers.

    To view Dr. Hwai-I Yang's publications, visit PubMed

    About the Creator
    Dr. Hwai-I Yang
    Guidelines